News
The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...
Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...
Moderna Inc. has agreed to do a placebo-controlled trial of its new Covid vaccine that was recently approved by US regulators ...
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...
Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...
The second of this two-part article explores what organizations should consider when trying to optimize a mixed team of ...
The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...
The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...
The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic ...
From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results